Tel Aviv-based Pulsenmore, developer of the world’s first home ultrasound device for pregnant women, surged 33% after receiving FDA clearance to market its product, paving the way for entry into the American market pulsenmore_home_ultrasound *** Shares of Pulsenmore, the Israeli pioneer of at-home ultrasound for pregnant women, jumped 33% Sunday on the Tel Aviv Stock Exchange after the company announced it had received FDA clearance to sell its device in the United States. The Pulsenmore ES allows expectant mothers to perform ultrasound scans at home in two ways: through a cradle that connects to a smartphone and transmits data, or under the remote guidance of a medical professional via telemedicine. The regulatory pathway approved by the U.S. Food and Drug Administration is among the agency’s most rigorous, requiring compliance with high standards of safety, quality, and clinical effectiveness. “This FDA approval marks a significant milestone for the company and paves the way fo...